热门资讯> 正文
Zevra Therapeutics报告第二季度业绩
2024-08-14 22:52
- Zevra Therapeutics press release (NASDAQ:ZVRA): Q2 GAAP EPS of -$0.48 misses by $0.04.
- Revenue of $4.45M (-47.4% Y/Y).
More on Zevra Therapeutics
- Zevra Therapeutics Q2 2024 Earnings Preview
- Zevra Therapeutics stock slides after pricing stock offering to raise $60 million
- Seeking Alpha’s Quant Rating on Zevra Therapeutics
- Historical earnings data for Zevra Therapeutics
- Financial information for Zevra Therapeutics
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。